Pharmaceutical Technology on MSN10h
Coave Therapeutics raises $33m in funding to advance ALIGATER platform
Coave has raised €32m ($33m) in a Series A financing round for advancing its Advanced Vectors-Ligand Conjugates (ALIGATER) platform.
GEN3d
Major Trends in Cell and Gene Therapy
The science has proven that gene therapies are effective treatments, and they have given hope to patients and their families ...
Oribiotech Ltd: Ori Biotech Expands Team to Advance IRO Commercialization and Industry Partnerships
Company Making Additions to Executive Team and Advisory Board to Support Significant Commercial MomentumLONDON, Jan. 09, 2025(Ori), a leader in cell and gene therapy (CGT) manufacturing technology, to ...
Pharmaceutical Technology on MSN2d
Vertex and Orna sign partnership to improve efficiencies of gene therapies
Orna will receive a $65m upfront payment and is eligible to receive potential milestone payments and royalties.
Danaher: A Wide-Moat Gem I Cannot Buy Enough Of
Discover why Danaher is a strong investment choice with its wide moat business model, M&A strategy, and growth potential for ...
Cell Therapy Technologies Market to Hit US$ 6.80 Billion by 2029 with 11.0% CAGR | MarketsandMarkets™
The global Cell Therapy Technologies market, valued at US$3.89 billion in 2023, is forecasted to grow at a robust CAGR of 11.0%, ...
eLife3d
A pair of congenic mice for imaging of transplants by positron emission tomography using anti-transferrin receptor nanobodies
Two anti-transferrin receptor (TfR) nanobodies, V H H123 specific for mouse TfR and V H H188 specific for human TfR (huTfR) were used to track transplants non-invasively by PET/CT in mouse models, ...
eLife4d
Plural molecular and cellular mechanisms of pore domain KCNQ2 encephalopathy
A single amino acid change in a neuronal ion channel called KCNQ2 blocks ion flow, prevents protein localization on axons, and results in severe epilepsy and slowed neurological development.